#Japan #Tokyo #Inflammatory Bowel Disease #J&J #I-BUDDY

Johnson & Johnson Launches I-BUDDY to Support IBD Patients

On the occasion of “Day of Understanding IBD,” Johnson & Johnson (J&J) announced the launch of “I-BUDDY,” a new initiative designed to assist individuals living with Inflammatory Bowel Disease (IBD). This initiative expands upon J&J's earlier efforts in their “Dual Control: Balancing Treatment and Work” campaign, which started in 2025. IBD comprises conditions like Ulcerative Colitis (UC) and Crohn's Disease (CD), both of which can significantly impact patients' lives, particularly their ability to work and pursue personal goals.

Recent data presented at the Digestive Disease Week (DDW) 2026 indicated a critical awareness gap; over 60% of IBD patients are unaware of the importance of achieving endoscopic remission—a state where no active lesions are observed during colonoscopy. This state is linked to improved long-term outcomes for patients, including a substantial reduction in symptom flare-ups and decreased likelihood of requiring surgeries related to IBD. Specifically, achieving endoscopic remission has shown to reduce the risk of worsening symptoms by 68% for UC patients and lowers related surgery needs by 75%. For CD patients, the risk drops by 41% with a one-third reduction in surgery necessity.

Given these findings, J&J emphasizes the importance of shared decision-making between patients and healthcare providers. This relation is vital to demystifying remission and ensuring patients understand what it entails for their long-term health outcomes. The “Dual Control” initiative aims to bridge this knowledge gap by showcasing stories from healthcare providers, family, and friends—essentially “buddies”—who help support IBD patients in navigating their treatment and work-life balance.

“I-BUDDY” is not just about medical treatment; it represents a holistic approach to patient care. Through this project, J&J seeks to highlight real-life stories of how these collaborations improve the quality of care provided to IBD patients. By using these narratives, the initiative aspires to raise awareness about shared decision-making practices, ultimately empowering patients to control their symptoms and strive for better disease management and quality of life.

Here’s an overview of the facts regarding IBD:

• - IBD refers to chronic inflammation of the intestines due to immune system malfunctions, encapsulating both UC and CD.
• - Symptoms such as diarrhea, abdominal pain, and blood in stool often emerge during adolescence, leaving these young individuals coping with life-altering decisions about their education and careers.
• - Globally, around 10 million people are affected by IBD, with rising prevalence noted in Asia, particularly in Japan where about 310,000 cases of UC and 90,000 cases of CD are estimated.

The “IBD Work Project” started in 2019 with support from entities like the NPO IBD Network and General Partners, specializing in employment transition for patients with chronic conditions, has laid the groundwork for the current “Dual Control” movement.

J&J continues to push for innovation in healthcare through patient-focused initiatives, affirming their belief that health is paramount. The company is dedicated to reshaping treatment norms to be more inclusive and effective, ensuring patients have access to necessary medications at crucial moments. Looking ahead, J&J Innovative Medicine reaffirms its commitment to patient well-being, exemplifying how understanding and managing conditions like IBD can lead to enhanced life experiences.

As the initiative gathers steam, J&J encourages everyone involved in the IBD community to engage with these stories actively and to leverage the power of shared insights. Whether through family, friends, or healthcare providers, the journey to better health and fulfillment for those living with IBD is a collective effort, aided significantly by awareness and understanding.